Berlinda J. Van Der Veen-De Wit
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 12, 2026
[195mPt]Cisplatin for lung cancer imaging: a pilot study.
Journal: EJNMMI research
Published: May 09, 2025
Clinical benefits of LAFOV PET/CT in growing demand for molecular imaging.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 27, 2025
Metabolic parameters on baseline and early [18F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma.
Journal: EJNMMI research
Published: February 01, 2025
Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET.
Journal: EJNMMI research
Published: November 29, 2023
Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model.
Journal: EJNMMI physics
Published: September 25, 2023
The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 01, 2023
Predicting the effect of different folate doses on [68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling.
Journal: EJNMMI research
Published: April 18, 2023
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling.
Journal: EJNMMI physics
Published: March 20, 2023
Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177 Lu-PSMA-617 in prostate cancer patients.
Journal: CPT: pharmacometrics & systems pharmacology
Published: August 30, 2022
Last Updated: 09/26/2026